Vaxess Receives National Institutes of Health Grant to Explore Administering Type 2 Diabetes Treatment via the MIMIX™ Transdermal Patch Platform
The National Institute of Diabetes and Digestive and Kidney Diseases Awards Vaxess SBIR Phase I Funding to Test Company’s MIMIX Transdermal Patch Platform in Administering GLP-1 RA Therapies
Excerpt from the Press Release:
CAMBRIDGE, Mass., October 1, 2024 — Vaxess Technologies, Inc., a biotech company developing a novel transdermal patch technology to transform home delivery of therapies and vaccines, today announced that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH). Vaxess will use this funding to build on the company’s existing efforts in GLP-1, exploring how its proprietary MIMIX transdermal patch platform can enable simple and effective GLP-1 RA at-home delivery for people with type 2 diabetes (T2D).
Over 400 million adults worldwide are living with T2D. Despite significant advancements in effective treatments, T2D continues to rise at a concerning rate, and by 2035 it is projected that there will be more than 590 million patients diagnosed globally with this condition — making it one of the costliest chronic health conditions for patients and society.
“GLP-1 RA therapies have revolutionized the treatment of T2D because they provide substantial reductions in blood sugar levels as well as address the underlying metabolic dysfunction of obesity that both can cause and complicate the management of diabetes,” said Livio Valenti, co-founder and SVP of strategy, operations and business development of Vaxess. “Unfortunately, poor adherence linked to perceived treatment complexity and fears of needles and injections remain a general problem. These barriers highlight the critical need for new modes of GLP-1 RA delivery.”
Vaxess’s MIMIX platform is a clinically demonstrated, transdermal microarray patch (MAP) characterized by slowly dissolving tips that ‘deploy’ into the dermis following patch application. The company’s work has demonstrated good compatibility of the GLP-1 RA, semaglutide, with the MIMIX production process.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?